U.S. MARKETS FOR TISSUE-ENGINEERED SKIN REPLACEMENTS/SUBSTITUTES AND ACTIVE WOUND REPAIR MODULATORS
Get the full unredacted version of this report by purchasing today.
In 2004, the United States (U.S.) market for tissue-engineered skin replacements/substitutes and active wound repair modulators, was valued at approximately $195 million. During the forecast period covered by this report, sales are expected to increase at a compound annual rate of 9.5%, reaching approximately $481 million in the year 2014.
This report from Medtech Insight includes analyses of products, competitors, current and forecast markets, opportunities in the U.S. skin replacements/substitutes and active wound repair modulators market, as well as technologies. Topics discussed in this report include allografts, autografts, extrinsic and intrinsic factors affecting wound closure, gene therapy agents, growth factors, major wound types, the physiology of wound closure, and xenografts.
i. Tissue-Engineered Skin Replacements/Substitutes
ii. Active Wound Repair Modulators
Exhibit ES-1: 2005, Skin Replacement Product Types
Exhibit ES-2: Tissue-Engineered Skin Replacements/Substitutes, Market Forecast, 2004-2014
Exhibit ES-3: Growth Factors, Market Forecast, 2004-2014
1. CLINICAL ISSUES IN WOUND MANAGEMENT
1.1 Physiology of Wound Closure
1.1.1 Layers of the Skin and Supporting Structures
126.96.36.199 Subcutaneous Tissue
1.1.2 Wound Closure Process
188.8.131.52 Remodeling Phase
1.2 Factors Affecting Wound Closure
1.2.1 Extrinsic Factors
184.108.40.206 Medications and Other Treatment Modalities
220.127.116.11 Necrotic Tissue and Debris
18.104.22.168 Wound Creation and Depth
22.214.171.124 Wound Closure Techniques
126.96.36.199 Other Extrinsic Factors
1.2.2 Intrinsic Factors
188.8.131.52 Body Build
184.108.40.206 Chronic Illness and Age
1.2.3 Complications of Wound Healing
1.3 Major Wound Types
1.3.2 Arterial Ulcers
1.3.4 Diabetic Ulcers
1.3.5 Pressure Ulcers
1.3.6 Surgical Wounds
1.3.7 Traumatic Wounds
1.3.8 Venous Ulcers
1.4 Incidence of Major Wound Types
Exhibit 1-1: The Skin's Layers and Supporting Structures
Exhibit 1-2: Phases of the Wound Closure Process
Exhibit 1-3: Intrinsic and Extrinsic Factors Affecting Wound Closure
Exhibit 1-4: Major Wound Types, by Cause
Exhibit 1-5: Stages of Burn Wounds
Exhibit 1-6: Stages of Pressure Ulcers
Exhibit 1-7: 2002, Inpatient and Outpatient Surgery, Procedure Volumes
Exhibit 1-8: 2004, Incidence of Major Wound Types
2. TISSUE-ENGINEERED SKIN REPLACEMENTS/SUBSTITUTES
2.4 Autologous and Tissue-Engineered Skin Replacements/Substitutes
2.4.1 Epidermal Equivalent Products
2.4.2 Dermal Equivalent Products
2.4.3 Multilayer Equivalent Products
2.5 Market Forecast
2.6 Competitive Analysis
Exhibit 2-1: 2005, Skin Replacement Product Types
Exhibit 2-2: 2005, Selected Current and Emerging Tissue-Engineered Skin Replacements/Substitutes
Exhibit 2-3: Tissue-Engineered Skin Replacements/Substitutes, Market Forecast, 2004-2014
Exhibit 2-4: 2004, Tissue-Engineered Skin Replacements/Substitutes Market, Share by Supplier
3. ACTIVE WOUND REPAIR MODULATORS
3.1 Growth Factors
3.1.1 Growth Factor Classification
220.127.116.11 Fibroblast Growth Factor
18.104.22.168 Transforming Growth Factor
22.214.171.124 Epidermal Growth Factor
126.96.36.199 Platelet-Derived Growth Factor
188.8.131.52 Insulin-Like Growth Factor
184.108.40.206 Keratinocyte Growth Factor
220.127.116.11 Vascular Endothelial Growth Factor
18.104.22.168 Autologous Growth Factor
22.214.171.124.3 Harvest Technologies
126.96.36.199.5 PlasmaSeal/Hanuman Medical
188.8.131.52 Summary of Angiogenic Growth Factors
3.1.2 Competitors and Products
3.1.3 Market Forecast
3.2 Gene Therapy Agents
3.3 Other Active Wound Repair Modulators and Pharmaceuticals
3.3.1 Antibiotics and Anti-Infectives
3.3.3 Matrix Metalloproteinase Enzyme Inhibitors
3.3.4 Neuropeptides in Diabetic Wounds
3.3.5 Stem Cells
3.3.6 Other Products
Exhibit 3-1: Selected Growth Factors in Development for Wound Healing Applications
Exhibit 3-2: 2005, Selected Angiogenic Growth Factors
Exhibit 3-3: Growth Factors, Market Forecast, 2004-2014
Exhibit 3-4: Preclinical Gene Therapy Studies, 1998-2004
4. COMPANY PROFILES
4.1 Biomet, Inc.
4.2 Ethicon, Inc./Johnson & Johnson
4.3 Genentech, Inc.
4.4 Genzyme Biosurgery, Inc./Genzyme Corporation
4.5 Healthpoint Ltd./DFB Pharmaceuticals, Inc.
4.6 Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
4.7 LifeCell Corporation
4.8 Organogenesis, Inc.
4.9 Ortec International, Inc.
4.10 RegeneRx Biopharmaceuticals, Inc.
4.11 Smith & Nephew plc
4.12 TEI Biosciences Inc.
- Biomet, Inc.
- Ethicon, Inc./Johnson & Johnson
- Genentech, Inc.
- Genzyme Biosurgery, Inc./Genzyme Corporation
- Healthpoint Ltd./DFB Pharmaceuticals, Inc
- Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
- LifeCell Corporation
- Organogenesis, Inc.
- Ortec International, Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Smith & Nephew plc
- TEI Biosciences Inc.
A Single License allows for one person to access the report. A Corporate License allows for multiple individuals within a company to access the report.